Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q1 2020 · 10-Q
Revenue$836.00K$836.00K+5,131.5% vs Q1 2019 Net Income-$2.82M-$2.82MN/M vs Q1 2019 EPS Diluted-$0.06-$0.06N/M vs Q1 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Operating Cash Flow-$164,283N/M Free Cash Flowderived-$164,283N/M Margins · derivedGross margin-67.5%−88.6 pt vs Q1 2019
Operating margin-315.0%+15929.4 pt vs Q1 2019
Net margin-337.6%+8485.1 pt vs Q1 2019
ended Mar 31, 2020 · filed Jun 29, 2020 · 90 d after period end